NL-OMON51513招募中不适用
International multicenter observational study to determine the diagnostic sensitivity of plasma metanephrines and urinary catecholamines and metabolites compared to standard evaluation procedures in children with high risk neuroblastoma - Metanephrines
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 0 至 17（—）
入选标准
- •Patients with confirmed high risk neuroblastoma (clinical and/or biological)
- •Patients treated within or according to SIOPEN HR-NBL-2 clinical trial
- •Age < 18 years at inclusion, male or female
- •Ethic committee approval for each participating site
- •Informed consent signed by the legal representatives and/or by the child
- •according to local regulations
排除标准
- •Renal insufficiency (creatinine clearance according to Schwartz formula <
- •60ml/min/m2)
- •Absence of histological confirmation of high risk neuroblastoma
- •Lack of consent
研究者
相似试验
尚未招募
不适用
International Multi-Center Observational Study of Lung-protective Ventilation in Asian ICUsDiseases of th respiratory systemKCT0004270Asan Medical Center1,000
尚未招募
不适用
A study international multi center study to find out the current practices using in patient admitted in intensive care unit while giving breathing with the help of artificial breathing machine in intensive care units across all Asia.CTRI/2019/07/020215Tata Memorial Hospital
进行中（未招募）
不适用
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-013884-21-DEEnceladus Pharmaceuticals BV90
进行中（未招募）
1 期
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)EUCTR2009-013884-21-BEEnceladus Pharmaceuticals BV90
进行中（未招募）
不适用
A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-013884-21-PLEnceladus Pharmaceuticals BV90